Concepedia

Publication | Open Access

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

DOIFull Paper Access

278

Citations

30

References

2016

Year

Vincent Leroy, Peter Angus, Jean–Pierre Bronowicki, Gregory J. Dore, Christophe Hézode, Stephen Pianko, Stanislas Pol, Katherine Stuart, Edmund Tse, Fiona McPhee,
Hepatology

Abstract

The all-oral regimen of DCV-SOF-RBV was well tolerated and resulted in high and similar SVR12 after 12 or 16 weeks of treatment among genotype 3-infected patients with advanced liver disease, irrespective of past HCV treatment experience.

References

YearCitations

Page 1